Adalimumab is a blockbuster fully human monoclonal antibody categorized as a tumor necrosis factor (TNF) inhibitor. It functions by specifically binding to and neutralizing TNF-alpha, a key inflammatory cytokine that drives systemic inflammation and tissue destruction. Prescribed widely under brand names like Humira, it is utilized as an advanced biologic therapy to treat severe chronic inflammatory and autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and plaque psoriasis.